EUROPEAN PATENT OFFICE
U.S. PATENT AND TRADEMARK OFFICE

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

The following classification changes will be effected by this Notice of Changes:

Action	**Subclass**	**Group(s)**
Symbols deleted:	A61K	8/975
	A61K	47/48, 47/48007, 47/48015, 47/48023, 47/4803, 47/48038, 47/48046, 47/48053, 47/48061, 47/48069, 47/48076, 47/48084, 47/48092, 47/481, 47/48107, 47/48115, 47/48123, 47/4813, 47/48138, 47/48146, 47/48153, 47/48161, 47/48169, 47/48176, 47/48184, 47/48192, 47/482, 47/48207, 47/48215, 47/48223, 47/4823, 47/48238, 47/48246, 47/48253, 47/48261, 47/48269, 47/48276, 47/48284, 47/48292, 47/483, 47/48307, 47/48315, 47/48323, 47/4833, 47/48338, 47/48346, 47/48353, 47/48361, 47/48369, 47/48376, 47/48384, 47/48392, 47/484, 47/48407, 47/48415, 47/48423, 47/4843, 47/48438, 47/48446, 47/48453, 47/48461, 47/48469, 47/48476, 47/48484, 47/48492, 47/485, 47/48507, 47/48515, 47/48523, 47/4853, 47/48538, 47/48546, 47/48553, 47/48561, 47/48569, 47/48576, 47/48584, 47/48592, 47/486, 47/48607, 47/48615, 47/48623, 47/4863, 47/48638, 47/48646, 47/48653, 47/48661, 47/48669, 47/48676, 47/48684, 47/48692, 47/487, 47/48707, 47/48715, 47/48723, 47/4873, 47/48738, 47/48746, 47/48753, 47/48761, 47/48769, 47/48776, 47/48784, 47/48792, 47/488, 47/48807, 47/48815, 47/48823, 47/4883, 47/48838, 47/48846, 47/48853, 47/48861, 47/48869, 47/48876, 47/48884, 47/48892, 47/489, 47/48907, 47/48915, 47/48923, 47/4893, 47/48938, 47/48946, 47/48953, 47/48961, 47/48969, 47/48976, 47/48984, 47/48992
Symbols newly created:	A61K	8/9706, 8/9711, 8/9717, 8/9722, 8/9728, 8/9733, 8/9739, 8/9741, 8/9749, 8/9755, 8/9761, 8/9767, 8/9771, 8/9778, 8/9783, 8/9789, 8/9794
	A61K	47/50, 47/51, 47/52, 47/54, 47/541, 47/542, 47/543, 47/544, 47/545, 47/546, 47/547, 47/548, 47/549, 47/55, 47/551, 47/552, 47/554, 47/555, 47/556, 47/557, 47/558, 47/559, 47/56, 47/58, 47/585, 47/59, 47/593, 47/595, 47/60, 47/605, 47/61, 47/62, 47/64, 47/641, 47/6415, 47/642, 47/6425, 47/643, 47/6435, 47/644, 47/6445, 47/645, 47/6455, 47/646, 47/65, 47/66, 47/665, 47/67, 47/68, 47/6801, 47/6803, 47/6805, 47/6807, 47/6809, 47/6811, 47/6813, 47/6815, 47/6817, 47/6819, 47/6821, 47/6823, 47/6825, 47/6827, 47/6829, 47/6831, 47/6833, 47/6835, 47/6839, 47/6841,47/6843, 47/6845, 47/6847, 47/6849, 47/6851, 47/6853, 47/6855, 47/6857, 47/6859, 47/6861, 47/6863, 47/6865, 47/6867, 47/6869, 47/6871, 47/6873, 47/6875, 47/6877, 47/6879, 47/6881, 47/6883, 47/6885, 47/6887, 47/6889, 47/6891, 47/6893, 47/6895, 47/6897, 47/6898, 47/6899, 47/69, 47/6901, 47/6903, 47/6905, 47/6907, 47/6909, 47/6911, 47/6913, 47/6915, 47/6917, 47/6919, 47/6921, 47/6923, 47/6925, 47/6927, 47/6929, 47/6931, 47/6933, 47/6935, 47/6937, 47/6939, 47/6941, 47/6943, 47/6949, 47/6951, 47/6953, 47/6955, 47/6957
Title Change	A61K	8/97, 8/99
	A61K	9/1271, 9/1272

	A61K	47/00, 47/06, 47/10, 47/14, 47/18, 47/183, 47/186, 47/20, 47/22, 47/24, 47/26, 47/28, 47/30, 47/32, 47/34, 47/36, 47/40, 47/42, 47/44, 47/46
Deleted definitions:	A61K	47/48, 47/48092, 47/481
Modified definitions:	A61K	8/97, 8/99
	A61K	47/00
New definitions:	A61K	47/34, 47/50, 47/52, 47/543, 47/546, 47/547, 47/548, 47/549, 47/55, 47/554, 47/555, 47/556, 47/558, 47/56, 47/61, 47/62, 47/64, 47/646, 47/66, 47/67, 47/6803, 47/6835, 47/6891, 47/6898 47/6899, 47/69, 47/6901, 47/6907, 47/6911, 47/6913, 47/6915, 47/6923, 47/6925, 47/6927, 47/6929
Scheme Warning Notices to be added	A61K	8/97, 8/9706,8/9728, 8/9733, 8/9739, 8/9741, 8/9749, 8/9755, 8/9771, 8/9778, 8/9783, 8/99
	A61K	47/183, 47/186
Scheme Notes to be deleted:	A61K	41/0052
	A61K	47/34, 47/48007, 47/48015, 47/48038, 47/48046, 47/48069, 47/48076, 47/48084, 47/48092, 47/481, 47/48123, 47/4813, 47/48138,47/48146,47/48153, 47/48169, 47/4823, 47/48238, 47/48246, 47/48269, 47/48276, 47/4833, 47/48346, 47/48353, 47/48361,47/48376, 47/48384, 47/48507, 47/48723, 47/48753, 47/48761, 47/48769, 47/48776, 47/488, 47/48815, 47/48823, 47/4883, 47/48861, 47/48869, 47/48876, 47/48884, 47/48892, 49/1851

The following subclasses/groups are also impacted by this Notice of Changes:
A23F, B01J, C07K, C08B, C08G, C08H, C08J, C12P

This Notice of Changes includes the following *[Check the ones included]:*

1. CLASSIFICATION SCHEME CHANGES
   - ☒ A. New, Modified or Deleted Group(s)
   - ☒ B. New, Modified or Deleted Warning Notice(s)
   - ☒ C. New, Modified or Deleted Note(s)
   - ☐ D. New, Modified or Deleted Guidance Heading(s)
2. DEFINITIONS (New or Modified)
   - ☒ A. DEFINITIONS (Full definition template)
   - ☒ B. DEFINITIONS (Definitions Quick Fix)
3. ☒ REVISION CONCORDANCE LIST (RCL)
4. ☒ CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)
5. ☒ CROSS-REFERENCE LIST (CRL)

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

1. CLASSIFICATION SCHEME CHANGES

A. New, Modified or Deleted Group(s)

SUBCLASS A61K PREPARATION FOR MEDICAL, DENTAL OR TOILET PURPOSES

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
C	A61K8/97	3	from algae, fungi, lichens or plants; from derivatives thereof	A61K 8/97, A61K 8/9706, A61K 8/9711, A61K 8/9717, A61K 8/9722, A61K 8/9728, A61K 8/9733, A61K 8/9739, A61K 8/9741, A61K 8/9749, A61K 8/9755, A61K 8/9761, A61K 8/9767, A61K 8/9771, A61K 8/9778, A61K 8/9783, A61K 8/9789, A61K 8/9794
D	A61K8/975	4	{Pollen; Algae, Higher fungi}	<administrative transfer to A61K 8/9706>
Q	A61K8/9706	4	Algae	A61K 8/9706, A61K 8/9711, A61K 8/9717, A61K 8/9722, A61K 8/9728, A61K 8/9733, A61K 8/9739, A61K 8/9741, A61K 8/9749, A61K 8/9755, A61K 8/9761, A61K 8/9767, A61K 8/9771, A61K 8/9778, A61K 8/9783, A61K 8/9789, A61K 8/9794

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
N	A61K8/9711	5	Phaeophycota or Phaeophyta [brown algae], e.g. Fucus	
N	A61K8/9717	5	Rhodophycota or Rhodophyta [red algae], e.g. Porphyra	
N	A61K8/9722	5	Chlorophycota or Chlorophyta [green algae], e.g. Chlorella	
N	A61K8/9728	4	Fungi, e.g. yeasts	
N	A61K8/9733	4	Lichens	
N	A61K8/9739	4	Bryophyta [mosses]	
N	A61K8/9741	4	Pteridophyta [ferns]	
N	A61K8/9749	5	Filicopsida or Pteridopsida	
N	A61K8/9755	4	Gymnosperms [Coniferophyta]	
N	A61K8/9761	5	Cupressaceae [Cypress family], e.g. juniper or cypress	
N	A61K8/9767	5	Pinaceae [Pine family], e.g. pine or cedar	
N	A61K8/9771	4	Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]	
N	A61K8/9778	4	Gnetophyta, e.g. Ephedraceae [Mormon-tea family]	
N	A61K8/9783	4	Angiosperms [Magnoliophyta]	
N	A61K8/9789	5	Magnoliopsida [dicotyledons]	
N	A61K8/9794	5	Liliopsida [monocotyledons]	
C	A61K8/99	3	from microorganisms other than algae or fungi, e.g. protozoa or bacteria	A61K 8/99, A61K 8/9706, A61K 8/9728
M	A61K9/1271	3	{Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers (liposome as conjugate A61K 47/6911)}	
M	A61K9/1272	4	{with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids (with cholesterol as the only non-phosphatidyl surfactant A61K 9/127; lipids as modifying agent A61K 47/543)}	
U	A61K45/06	1	Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca	
M	A61K47/00	0	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient	
M	A61K47/06	1	Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite	
M	A61K47/10	3	Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers	

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
M	A61K47/14	3	Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters	
M	A61K47/18	3	Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids	
C	A61K 47/183	4	{Amino acids, e.g. glycine, EDTA or aspartame}	A61K 47/183, A61K 47/20, A61K47/22, A61K47/26, A61K47/28
C	A61K47/186	4	{Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}	A61K 47/186, A61K 47/20, A61K47/22, A61K47/26, A61K47/28
E	A61K47/20	2	containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids	
E	A61K47/22	2	Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones	
M	A61K47/24	2	containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids	
E	A61K47/26	2	Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin	
E	A61K47/28	2	Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid	
M	A61K47/30	1	Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates	
M	A61K47/32	2	Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}	
M	A61K47/34	2	Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K 47/10 takes precedence)	
M	A61K47/36	2	Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin	
M	A61K47/40	3	Cyclodextrins; Derivatives thereof	

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
M	A61K47/42	2	Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K 47/183}; polyamino acids A61K 47/34)	
M	A61K47/44	1	Oils, fats or waxes according to two or more groups of A61K 47/02-A61K 47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K 47/14)	
M	A61K47/46	1	Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts	
D	A61K47/48	1	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates	<administrative transfer to A61K47/50>
D	A61K47/48007	2	{the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent}	<administrative transfer to A61K47/51>
D	A61K47/48015	3	{the modifying agent being an inorganic compound, e.g. inorganic ion that being chemically complexed with the pharmacologically- or therapeutically-active agent (A61K47/48161 takes precedence)}	<administrative transfer to A61K47/52>
D	A61K47/48023	3	{the modifying agent being an organic compound (A61K47/48161 takes precedence)}	<administrative transfer to A61K47/54>
D	A61K47/4803	4	{the modifying agent being an organic ion that forms an ion pair complex with the pharmacologically or therapeutically active agent}	<administrative transfer to A61K47/541>
D	A61K47/48038	4	{the modifying agent being a carboxylic acid, e.g. a fatty acid or an amino acid}	<administrative transfer to A61K47/542>
D	A61K47/48046	4	{the modifying agent being a lipid, e.g. a triglyceride; the modifying agent being a polyamine, e.g. spermine or spermidine}	<administrative transfer to A61K47/543>
D	A61K47/48053	5	{the modifying agent being a phospholipid}	<administrative transfer to A61K47/544>
D	A61K47/48061	4	{the modifying agent being a heterocyclic compound (A61K47/48153 takes precedence)}	<administrative transfer to A61K47/545>
D	A61K47/48069	5	{the modifying agent being a heterocyclic compound which being a porphyrine or a	<administrative transfer to A61K47/546>

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
			porphyrine with an expanded ring system, e.g. texaphyrine}	
D	A61K47/48076	4	{the modifying agent being a chelate, i.e. single central atom/ion sequestered by a polydentate ligand, e.g. Gd-DOTA or Zinc-amino acid chelate, or a chelate-forming compound, i.e. chelating group, e.g. DOTA or ethylenediamine, that being covalently/complexed to the pharmacologically- or therapeutically-active agent}	<administrative transfer to A61K47/547>
D	A61K47/48084	4	{the modifying agent being a phosphate or phosphonate not being a phospholipid, e.g. bone-seeking}	<administrative transfer to A61K47/548>
D	A61K47/48092	4	{the modifying agent linked to the pharmacologically or therapeutically active agent being a sugar, nucleoside, nucleotide, nucleic acid}	<administrative transfer to A61K47/549>
D	A61K47/481	4	{the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds, e.g. a polymer of aspirin}	<administrative transfer to A61K47/55>
D	A61K47/48107	5	{one of the codrug's components being a vitamin, e.g. niacinamide (vitamin B3), cobalamin (vitamin B12), folate, vitamin A, retinoic acid}	<administrative transfer to A61K47/551>
D	A61K47/48115	5	{one of the codrug's components being an antibiotic}	<administrative transfer to A61K47/552>
D	A61K47/48123	4	{the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone, bile acid}	<administrative transfer to A61K47/554>
D	A61K47/4813	4	{pretargeting systems involving an organic compound, not being a peptide, protein or antibody, for targeting specific cells}	<administrative transfer to A61K47/555>
D	A61K47/48138	5	{ECTA, enzyme catalyzed therapeutic agent}	<administrative transfer to A61K47/556>
D	A61K47/48146	5	{the modifying agent being biotin}	<administrative transfer to A61K47/557>
D	A61K47/48153	4	{the modifying agent being a chemiluminescent acceptor}	<administrative transfer to A61K47/558>
D	A61K47/48161	4	{Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems}	<administrative transfer to A61K47/559>
D	A61K47/48169	2	{the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule}	<administrative transfer to A61K47/56>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48176	3	{the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol}	<administrative transfer to A61K47/58>
D	A61K47/48184	4	{the macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds being an ion exchange resin, e.g. polystyrene sulfonic acid resin}	<administrative transfer to A61K47/585>
D	A61K47/48192	3	{the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes}	<administrative transfer to A61K47/59>
D	A61K47/482	4	{the macromolecule is/contains a polyester, e.g. PLGA, polylactide-co-glycolide}	<administrative transfer to A61K47/593>
D	A61K47/48207	4	{the macromolecule is/contains a polyamide, e.g. nylon (polyamino acids A61K47/48238)}	<administrative transfer to A61K47/595>
D	A61K47/48215	4	{the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer, e.g. PEG, PPG, PEO, polyglycerol}	<administrative transfer to A61K47/60>
D	A61K47/48223	4	{the macromolecule contains phosphorus in the main chain, e.g. poly-phosphazene}	<administrative transfer to A61K47/605>
D	A61K47/4823	3	{the organic macromolecular compound being a polysaccharide or a derivative, e.g. starch, chitosan, chitin, cellulose, pectin, cyclodextrin with the pharmacologically active agent being covalently linked to the external surface of the ring structure, a bacterial polysaccharide or oligosaccharide antigen, a glycosaminoglycan}	<administrative transfer to A61K47/61>
D	A61K47/48238	2	{the modifying agent being a protein, peptide, polyamino acid}	<administrative transfer to A61K47/62>
D	A61K47/48246	3	{drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent (peptidic linker are classified in A61K47/48338)}	<administrative transfer to A61K47/64>
D	A61K47/48253	4	{the peptide, protein or polyamino acid in the drug conjugate being a branched, dendritic or hypercomb peptide}	<administrative transfer to A61K47/641>
D	A61K47/48261	4	{the peptide or protein in the drug conjugate being a toxin or a lectin, e.g. clostridial toxins or Pseudomonas exotoxin}	<administrative transfer to A61K47/6415>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48269	4	{the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors, interferons being the inactive part of the conjugate}	<administrative transfer to A61K47/642>
D	A61K47/48276	4	{the peptide or protein in the drug conjugate being a receptor as such, e.g. CD4; a cell surface antigen (therefore not a peptide ligand targeting the antigen); a cell surface determinant, i.e. a part of the surface of a cell}	<administrative transfer to A61K47/6425>
D	A61K47/48284	4	{the peptide or protein in the drug conjugate being an albumin, e.g. HSA, BSA, ovalbumin, or a Keyhole Limpet Hemocyanin [KHL]}	<administrative transfer to A61K47/643>
D	A61K47/48292	4	{the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin, gelatin}	<administrative transfer to A61K47/6435>
D	A61K47/483	4	{the peptide or protein in the drug conjugate being a transferrin, e.g. a lactoferrin or ovotransferrin}	<administrative transfer to A61K47/644>
D	A61K47/48307	4	{the peptide or protein in the drug conjugate being a haemoglobin}	<administrative transfer to A61K47/6445>
D	A61K47/48315	4	{the peptide or protein in the drug conjugate being a polycationic or polyanionic oligopeptide, polypeptide or polyamino acid, e.g. polylysine, polyarginine, polyglutamic acid, peptide TAT}	<administrative transfer to A61K47/645>
D	A61K47/48323	5	{polyanionic oligopeptide, polypeptide or polyamino acid, used to complex nucleic acids being the therapeutic agent}	<administrative transfer to A61K47/6455>
D	A61K47/4833	4	{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}	<administrative transfer to A61K47/646>
D	A61K47/48338	3	{peptidic linker, binder, spacer, e.g. peptidic enzyme-labile linker}	<administrative transfer to A61K47/65>
D	A61K47/48346	3	{pretargeting systems involving a peptide or protein (not an antibody A61K47/48723)for targeting specific cells}	<administrative transfer to A61K47/66>
D	A61K47/48353	4	{pretargeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}	<administrative transfer to A61K47/665>
D	A61K47/48361	4	{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT], VDEPT}	<administrative transfer to A61K47/67>
D	A61K47/48369	2	{the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment}	<administrative transfer to A61K47/68>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48376	3	{drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}	<administrative transfer to A61K47/6801>
D	A61K47/48384	4	{drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}	<administrative transfer to A61K47/6803>
D	A61K47/48392	5	{the drug being a vinca alkaloid}	<administrative transfer to A61K47/6805>
D	A61K47/484	5	{the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}	<administrative transfer to A61K47/6807>
D	A61K47/48407	6	{the drug being an antibiotic, e.g. one of the antitumor antibiotics: anthracyclins, adriamycin, doxorubicin, daunomycin}	<administrative transfer to A61K47/6809>
D	A61K47/48415	5	{the drug being a protein or peptide, e.g. transferrin or bleomycin}	<administrative transfer to A61K47/6811>
D	A61K47/48423	6	{the drug being a peptidic cytokine, e.g. an interleukin or interferon}	<administrative transfer to A61K47/6813>
D	A61K47/4843	6	{the drug being an enzyme}	<administrative transfer to A61K47/6815>
D	A61K47/48438	6	{the drug being a toxin}	<administrative transfer to A61K47/6817>
D	A61K47/48446	7	{the drug being a plant toxin}	<administrative transfer to A61K47/6819>
D	A61K47/48453	8	{the drug being a plant heterodimeric toxin; chains A or B containing toxins, e.g. abrin, modeccin}	<administrative transfer to A61K47/6821>
D	A61K47/48461	9	{the drug being ricin (double chain)}	<administrative transfer to A61K47/6823>
D	A61K47/48469	8	{the drug being a ribosomal inhibitory protein,(RIP-i or RIP-II), e.g. Pap, gelonin, dianthin}	<administrative transfer to A61K47/6825>
D	A61K47/48476	9	{the drug being ricin A}	<administrative transfer to A61K47/6827>
D	A61K47/48484	7	{the drug being a bacterial toxin, e.g. diphteria toxin, Pseudomonas exotoxin A}	<administrative transfer to A61K47/6829>
D	A61K47/48492	7	{the drug being a fungal toxin, e.g. alpha sarcine, mitogillin, zinniol, restrictocin}	<administrative transfer to A61K47/6831>
D	A61K47/485	7	{the drug being a viral toxin}	<administrative transfer to A61K47/6833>
D	A61K47/48507	3	{the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site}	<administrative transfer to A61K47/6835>
D	A61K47/48515	4	{not used; see subgroups}	<administrative transfer to A61K47/6835>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48523	5	{the antibody being against material from viruses}	<administrative transfer to A61K47/6839>
D	A61K47/4853	6	{the antibody being targeting a RNA virus}	<administrative transfer to A61K47/6841>
D	A61K47/48538	5	{the antibody being targeting a material from animals or humans}	<administrative transfer to A61K47/6843>
D	A61K47/48546	5	{the antibody being targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}	<administrative transfer to A61K47/6845>
D	A61K47/48553	5	{the antibody being targeting an hormone, or an hormone-releasing or -inhibiting factor}	<administrative transfer to A61K47/6847>
D	A61K47/48561	5	{the antibody being targeting a receptor, a cell surface antigen, a cell surface determinant}	<administrative transfer to A61K47/6849>
D	A61K47/48569	5	{the antibody being targeting a determinant of a tumour cell}	<administrative transfer to A61K47/6851>
D	A61K47/48576	6	{the tumour determinant being carcino-embryonic antigen}	<administrative transfer to A61K47/6853>
D	A61K47/48584	6	{the tumour determinant being from breast cancer cell}	<administrative transfer to A61K47/6855>
D	A61K47/48592	6	{the tumour determinant being from lung cancer cell}	<administrative transfer to A61K47/6857>
D	A61K47/486	6	{the tumour determinant being from liver or pancreas cancer cell}	<administrative transfer to A61K47/6859>
D	A61K47/48607	6	{the tumour determinant being from kidney or bladder cancer cell}	<administrative transfer to A61K47/6861>
D	A61K47/48615	6	{the tumour determinant being from stomach or intestines cancer cell}	<administrative transfer to A61K47/6863>
D	A61K47/48623	6	{the tumour determinant being from skin, nerves or brain cancer cell}	<administrative transfer to A61K47/6865>
D	A61K47/4863	6	{the tumour determinant being from a cell of a blood cancer}	<administrative transfer to A61K47/6867>
D	A61K47/48638	6	{the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}	<administrative transfer to A61K47/6869>
D	A61K47/48646	5	{the antibody being targeting an enzyme}	<administrative transfer to A61K47/6871>
D	A61K47/48653	5	{the antibody being targeting an immunoglobulin, being an anti-idiotypic antibody}	<administrative transfer to A61K47/6873>
D	A61K47/48661	5	{the antibody being a hybrid immunoglobulin}	<administrative transfer to A61K47/6875>
D	A61K47/48669	6	{the antibody being an immunoglobulin containing regions, domains, residues from different species}	<administrative transfer to A61K47/6877>

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
D	A61K47/48676	6	{the immunoglobulin has two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}	<administrative transfer to A61K47/6879>
D	A61K47/48684	4	{cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies that are covalently linked to each other, or of different antigen-binding fragments that are covalently linked to each other}	<administrative transfer to A61K47/6881>
D	A61K47/48692	4	{polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate, used for therapy}	<administrative transfer to A61K47/6883>
D	A61K47/487	5	{the conjugate or the polymer being a starburst, a dendrimer, a cascade}	<administrative transfer to A61K47/6885>
D	A61K47/48707	4	{antibody-chelate conjugate wherein the chelate being used for therapeutic purposes (when radioabeled and used in radiodiagnosis or radiotherapy A61K51/1093 and the corresponding A61K51/1003 subgroup; antibody-chelate used for MRI A61K49/14)}	<administrative transfer to A61K47/6887>
D	A61K47/48715	3	{conjugates wherein the antibody being the modifying agent and wherein the linker, binder, spacer confers particular properties to the conjugate, e.g. peptidic enzyme-labile linker or acid-labile linker giving rise to an acid-labile immunoconjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural, environment}	<administrative transfer to A61K47/6889>
D	A61K47/48723	3	{pretargeting systems involving an antibody for targeting specific cells}	<administrative transfer to A61K47/6891>
D	A61K47/4873	4	{clearing therapy or enhanced clearance, i.e. wherein an antibody clearing agent being used in addition to T-A and D-M according to the definitions in A61K47/48723}	<administrative transfer to A61K47/6893>
D	A61K47/48738	4	{rescue therapy; agonist-antagonist; antidote; targeted rescue or protection, e.g. folic acid-folinic acid, conjugated to antibodies both or only one}	<administrative transfer to A61K47/6895>
D	A61K47/48746	4	{two or three steps pretargeting systems, wherein an antibody conjugate being used in at least one of the steps; ligand-antiligand therapy}	<administrative transfer to A61K47/6897>
D	A61K47/48753	5	{avidin-biotin system wherein at least one avidin- or biotin-conjugated antibody being used in a two- or three-steps pretargeting system}	<administrative transfer to A61K47/6898>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48761	4	{ADEPT, i.e. Antibody Directed Enzyme Prodrug Therapy}	<administrative transfer to A61K47/6899>
D	A61K47/48769	2	{the conjugate being characterized by a special physical or galenical form}	<administrative transfer to A61K47/69>
D	A61K47/48776	3	{forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent}	<administrative transfer to A61K47/6901>
D	A61K47/48784	3	{the form being semi-solid, an ointment, a gel, a hydrogel, a solidifying gel}	<administrative transfer to A61K47/6903>
D	A61K47/48792	3	{the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension}	<administrative transfer to A61K47/6905>
D	A61K47/488	4	{the form being a micro-emulsion, nano-emulsion or micelle (Simple encapsulation of a drug in micelle: A61K9/1075)}	<administrative transfer to A61K47/6907>
D	A61K47/48807	5	{micelles formed by phospholipids}	<administrative transfer to A61K47/6909>
D	A61K47/48815	4	{the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent. (Simple encapsulation of a drug which being not functionalised on its surface by a modifying agent: see A61K9/127)}	<administrative transfer to A61K47/6911>
D	A61K47/48823	5	{the form being a liposome which being modified on its surface by an antibody}	<administrative transfer to A61K47/6913>
D	A61K47/4883	5	{the form being a polymersome, i.e. a liposome with polymerisable or polymerized bilayer-forming substances}	<administrative transfer to A61K47/6915>
D	A61K47/48838	4	{the form being a lipoprotein vesicle, e.g. HDL and LDL proteins}	<administrative transfer to A61K47/6917>
D	A61K47/48846	4	{the form being a ribbon, tubule cochleate}	<administrative transfer to A61K47/6919>
D	A61K47/48853	3	{the form being a particulate, powder, adsorbate, bead, sphere}	<administrative transfer to A61K47/6921>
D	A61K47/48861	4	{the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb}	<administrative transfer to A61K47/6923>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48869	4	{the form being a micro- or nano-capsule or a micro/nano-bubble, i.e. a hollow or gas micro- or nano-particle or sphere, a gas-filled micro- or nano-particle for use in therapy (Micro- or nano-bubbles used only for ultrasound imaging are classified in A61K49/223 or A61K49/225 only)}	<administrative transfer to A61K47/6925>
D	A61K47/48876	4	{the form being a solid micro- or nanoparticle having no hollow or gas-filled core}	<administrative transfer to A61K47/6927>
D	A61K47/48884	5	{the form being a nanoparticle, e.g. an immuno-nanoparticle}	<administrative transfer to A61K47/6929>
D	A61K47/48892	6	{the material constituting the nanoparticle being a polymer}	<administrative transfer to A61K47/6931>
D	A61K47/489	7	{the material constituting the nanoparticle being a polymer obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone, polyvinylalcohol}	<administrative transfer to A61K47/6933>
D	A61K47/48907	7	{the material constituting the nanoparticle being a polymer obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides, polyglycerol}	<administrative transfer to A61K47/6935>
D	A61K47/48915	8	{the polymer being PLGA, PLA or polyglycolic acid}	<administrative transfer to A61K47/6937>
D	A61K47/48923	7	{the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose, pectin}	<administrative transfer to A61K47/6939>
D	A61K47/4893	4	{the form being a granulate or an agglomerate}	<administrative transfer to A61K47/6941>
D	A61K47/48938	3	{the form being a pill, tablet, lozenge, capsule}	<administrative transfer to A61K47/6943>
D	A61K47/48946	3	{Microcapsules}	<administrative transfer to A61K47/6925>
D	A61K47/48953	4	{Nanocapsules; Nanoparticles, e.g. immunonanoparticles}	<administrative transfer to A61K47/6925>
D	A61K47/48961	3	{the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene}	<administrative transfer to A61K47/6949>
D	A61K47/48969	4	{inclusion being performed with a cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}	<administrative transfer to A61K47/6951>
D	A61K47/48976	3	{the form being a fibre, textile, slab, sheet}	<administrative transfer to A61K47/6953>
D	A61K47/48984	3	{the form being a plaster, bandage, dressing, patch}	<administrative transfer to A61K47/6955>

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
D	A61K47/48992	3	{the form being a device, kit .e.g. stent, microdevice}	<administrative transfer to A61K47/6957>
N	A61K47/50	1	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates	
N	A61K47/51	2	the non-active ingredient being a modifying agent	
N	A61K47/52	3	the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient	
N	A61K47/54	3	the modifying agent being an organic compound	
N	A61K47/541	4	{Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent}	
N	A61K47/542	4	{Carboxylic acids, e.g. a fatty acid or an amino acid}	
N	A61K47/543	4	{Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}	
N	A61K47/544	5	{Phospholipids}	
N	A61K47/545	4	{Heterocyclic compounds (A61K47/558 takes precedence)}	
N	A61K47/546	5	{Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine}	
N	A61K47/547	4	{Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds , e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}	
N	A61K47/548	4	{Phosphates or phosphonates , e.g. bone-seeking (phospholipids A61K 47/544)}	
N	A61K47/549	4	{Sugars, nucleosides, nucleotides or nucleic acids}	
N	A61K47/55	4	the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds	
N	A61K47/551	5	{one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}	
N	A61K47/552	5	{one of the codrug's components being an antibiotic}	

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61K47/554	4	{the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}	
N	A61K47/555	4	{pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}	
N	A61K47/556	5	{enzyme catalyzed therapeutic agent [ECTA]}	
N	A61K47/557	5	{the modifying agent being biotin}	
N	A61K47/558	4	{the modifying agent being a chemiluminescent acceptor}	
N	A61K47/559	4	{Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems}	
N	A61K47/56	3	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule	
N	A61K47/58	4	obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin	
N	A61K47/585	5	{Ion exchange resins, e.g. polystyrene sulfonic acid resin}	
N	A61K47/59	4	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes	
N	A61K47/593	5	{Polyesters, e.g. PLGA or polylactide-co-glycolide}	
N	A61K47/595	5	{Polyamides, e.g. nylon (polyamino acids A61K47/62)}	
N	A61K47/60	5	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol	
N	A61K47/605	5	{the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene}	
N	A61K47/61	4	the organic macromolecular compound being a polysaccharide or a derivative thereof	
N	A61K47/62	3	the modifying agent being a protein, peptide or polyamino acid	
N	A61K47/64	4	Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K 47/65)	

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
N	A61K47/641	5	{Branched, dendritic or hypercomb peptides}	
N	A61K47/6415	5	{Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}	
N	A61K47/642	5	{the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}	
N	A61K47/6425	5	{the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}	
N	A61K47/643	5	{Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}	
N	A61K47/6435	5	{the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin}	
N	A61K47/644	5	{Transferrin, e.g. a lactoferrin or ovotransferrin}	
N	A61K47/6445	5	{Haemoglobin}	
N	A61K47/645	5	{Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}	
N	A61K47/6455	6	{Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids }	
N	A61K47/646	5	{the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}	
N	A61K47/65	4	Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers	
N	A61K47/66	4	the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells	
N	A61K47/665	5	{the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems}	
N	A61K47/67	5	{Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}	
N	A61K47/68	3	the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment	
N	A61K47/6801	4	{Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}	

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61K47/6803	5	{Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}	
N	A61K47/6805	6	{the drug being a vinca alkaloid}	
N	A61K47/6807	6	{the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}	
N	A61K47/6809	7	{Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}	
N	A61K47/6811	6	{the drug being a protein or peptide, e.g. transferrin or bleomycin}	
N	A61K47/6813	7	{the drug being a peptidic cytokine, e.g. an interleukin or interferon}	
N	A61K47/6815	7	{Enzymes}	
N	A61K47/6817	7	{Toxins}	
N	A61K47/6819	8	{Plant toxins}	
N	A61K47/6821	9	{Plant heterodimeric toxins, e.g. abrin or modeccin}	
N	A61K47/6823	10	{Double chain ricin}	
N	A61K47/6825	9	{Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin}	
N	A61K47/6827	10	{Ricin A}	
N	A61K47/6829	8	{Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}	
N	A61K47/6831	8	{Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}	
N	A61K47/6833	8	{Viral toxins}	
N	A61K47/6835	4	{the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}	
N	A61K47/6839	5	{the antibody targeting material from viruses}	
N	A61K47/6841	6	{the antibody targeting a RNA virus}	
N	A61K47/6843	5	{the antibody targeting a material from animals or humans}	
N	A61K47/6845	5	{the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon}	
N	A61K47/6847	5	{the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}	
N	A61K47/6849	5	{the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}	
N	A61K47/6851	5	{the antibody targeting a determinant of a tumour cell}	
N	A61K47/6853	6	{Carcino-embryonic antigens}	

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
N	A61K47/6855	6	{the tumour determinant being from breast cancer cell}	
N	A61K47/6857	6	{the tumour determinant being from lung cancer cell}	
N	A61K47/6859	6	{the tumour determinant being from liver or pancreas cancer cell}	
N	A61K47/6861	6	{the tumour determinant being from kidney or bladder cancer cell}	
N	A61K47/6863	6	{the tumour determinant being from stomach or intestines cancer cell}	
N	A61K47/6865	6	{the tumour determinant being from skin, nerves or brain cancer cell}	
N	A61K47/6867	6	{the tumour determinant being from a cell of a blood cancer}	
N	A61K47/6869	6	{the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}	
N	A61K47/6871	5	{the antibody targeting an enzyme}	
N	A61K47/6873	5	{the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}	
N	A61K47/6875	5	{the antibody being a hybrid immunoglobulin}	
N	A61K47/6877	6	{the antibody being an immunoglobulin containing regions, domains or residues from different species}	
N	A61K47/6879	6	{the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}	
N	A61K47/6881	5	{Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other}	
N	A61K47/6883	5	{Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}	
N	A61K47/6885	6	{the conjugate or the polymer being a starburst, a dendrimer, a cascade}	
N	A61K47/6887	5	{Antibody-chelate conjugates using chelates for therapeutic purposes (radioactive substances, e.g. for use in radio diagnosis or radiotherapy, A61K51/10; antibody-chelates for use in MRI A61K49/14)}	
N	A61K47/6889	4	{Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the	

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}**	Transferred to#
			conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}	
N	A61K47/6891	4	{Pre-targeting systems involving an antibody for targeting specific cells}	
N	A61K47/6893	5	{clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M}	
N	A61K47/6895	5	{Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies}	
N	A61K47/6897	5	{Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}	
N	A61K47/6898	6	{using avidin- or biotin-conjugated antibodies}	
N	A61K47/6899	5	{Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}	
N	A61K47/69	2	the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit	
N	A61K47/6901	3	{Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}	
N	A61K47/6903	3	{the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}	
N	A61K47/6905	3	{the form being a colloid or an emulsion}	
N	A61K47/6907	4	{the form being a microemulsion, nanoemulsion or micelle}	
N	A61K47/6909	5	{Micelles formed by phospholipids}	
N	A61K47/6911	4	{the form being a liposome }	
N	A61K47/6913	5	{the liposome being modified on its surface by an antibody}	
N	A61K47/6915	5	{the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes }	
N	A61K47/6917	4	{the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}	
N	A61K47/6919	4	{the form being a ribbon or a tubule cochleate}	
N	A61K47/6921	3	{the form being a particulate, a powder, an adsorbate, a bead or a sphere}	
N	A61K47/6923	4	{the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}	

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Type*	**Symbol**	**Indent Level Number of dots (e.g. 0, 1, 2)**	**Title (new or modified) "CPC only" text should normally be enclosed in {curly brackets}****	**Transferred to#**
N	A61K47/6925	4	{the form being a microcapsule, nanocapsule, microbubble or nanobubble}	
N	A61K47/6927	4	{the form being a solid microparticle having no hollow or gas-filled cores}	
N	A61K47/6929	5	{the form being a nanoparticle, e.g. an immuno-nanoparticle}	
N	A61K47/6931	6	{the material constituting the nanoparticle being a polymer}	
N	A61K47/6933	7	{the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol}	
N	A61K47/6935	7	{the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}	
N	A61K47/6937	8	{the polymer being PLGA, PLA or polyglycolic acid}	
N	A61K47/6939	7	{the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}	
N	A61K47/6941	4	{the form being a granulate or an agglomerate}	
N	A61K47/6943	3	{the form being a pill, a tablet, a lozenge or a capsule}	
N	A61K47/6949	3	{ inclusion complexes, e.g. clathrates, cavitates or fullerenes}	
N	A61K47/6951	4	{using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}	
N	A61K47/6953	3	{the form being a fibre, a textile, a slab or a sheet}	
N	A61K47/6955	3	{the form being a plaster, a bandage, a dressing or a patch}	
N	A61K47/6957	3	{the form being a device or a kit, e.g. stents or microdevices}	

*N = new entries where reclassification into entries is involved; C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; E= existing entries with enlarged file scope, which receive documents from C or D entries, e.g. when a limiting reference is removed from the entry title; M = entries with no change to the file scope (no reclassification); D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed; U = entries that are unchanged.

NOTES:

- **No {curly brackets} are used for titles in CPC only subclasses, e.g. C12Y, A23Y; 2000 series symbol titles of groups found at the end of schemes (orthogonal codes); or the Y section titles. The {curly brackets} are used for 2000 series symbol titles found interspersed throughout the main trunk schemes (breakdown codes).

- For U groups, the minimum requirement is to include the U group located immediately prior to the N group or N group array, in order to show the N group hierarchy and improve the readability and understanding of the scheme. Always include the symbol, indent level and title of the U group in the table above.
- All entry types should be included in the scheme changes table above for better understanding of the overall scheme change picture. Symbol, indent level, and title are required for all types except "D" which requires only a symbol.
- #"Transferred to" column must be completed for all C, D, F, and Q type entries. F groups will be deleted once reclassification is completed.
- When multiple symbols are included in the "Transferred to" column, avoid using ranges of symbols in order to be as precise as possible.
- For administrative transfer of documents, the following text should be used: "< administrative transfer to XX>" or "<administrative transfer to XX and YY simultaneously>" when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be "invention information", unless otherwise indicated, and to 2000 series groups is assumed to be "additional information".

B. New, Modified or Deleted Warning notice(s)

SUBCLASS A61K PREPARATION FOR MEDICAL, DENTAL OR TOILET PURPOSES

Type*	Location	Old Warning notice	New/Modified Warning notice
N	A61K8/97		Group A61K8/97 is impacted by reclassification into groups A61K8/97-A61K8/9794. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K8/9706		1) Group A61K8/9706 is incomplete pending reclassification of documents from group A61K8/97. Groups A61K8/9706 and A61K8/97 should be considered in order to perform a complete search. 2) Group A61K8/9706 is also impacted by reclassification into groups A61K8/9706-A61K8/9794. All groups listed in this Warning should be considered in order to perform a complete search
N	A61K8/9711		Group A61K8/9711 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/97, A61K8/9706 and A61K8/9711 should be considered in order to perform a complete search.
N	A61K8/9717		Group A61K8/9717 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/97, A61K8/9706 and A61K8/9717 should be considered in order to perform a complete search.
N	A61K8/9722		Group A61K8/9722 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/97, A61K8/9706 and A61K8/9722 should be considered in order to perform a complete search.
N	A61K8/9728		Group A61K8/9728 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/9728, A61K8/97 and A61K8/9706 should be considered in order to perform a complete search.
N	A61K8/9733		Group A61K8/9733 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/9733 and A61K8/97 should be considered in order to perform a complete search.
N	A61K8/9739		Group A61K8/9739 is incomplete pending reclassification of documents from group A61K8/97. Groups A61K8/9739, A61K8/97 and A61K8/9706 should be considered in order to perform a complete search.

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Type*	Location	Old Warning notice	New/Modified Warning notice
N	A61K8/9741		Groups A61K8/9741 and A61K8/9749 are incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. All the groups listed in this Warning should be considered in order to perform a complete search.
N	A61K8/9755		Groups A61K8/9755, A61K8/9761 and A61K8/9767 are incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. All the groups listed in this Warning should be considered in order to perform a complete search.
N	A61K8/9771		Group A61K8/9771 is incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. Groups A61K8/9771 and A61K8/97 should be considered in order to perform a complete search.
N	A61K8/9778		Group A61K8/9778 is incomplete pending reclassification of documents from groupsA61K8/97 and A61K8/9706. Groups A61K8/9778, A61K8/97 and A61K8/9706 should be considered in order to perform a complete search.
N	A61K8/9783		Groups A61K8/9783, A61K8/9789 and A61K8/9794 are incomplete pending reclassification of documents from groups A61K8/97 and A61K8/9706. All the groups listed in this Warning should be considered in order to perform a complete search.
N	A61K8/99		Group A61K8/99 is impacted by reclassification into groups A61K8/9706 and A61K8/9728. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K 47/183		Group A61K 47/183 is impacted by reclassification into groups A61K 47/20, A61K 47/22, A61K 47/26 and A61K 47/28. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K 47/186		Group A61K 47/186 is impacted by reclassification into groups A61K 47/20, A61K 47/22, A61K 47/26 and A61K 47/28. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K 47/20		Group A61K47/20 is incomplete pending reclassification of documents from groups A61K47/183 and A61K47/186. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K47/22		Group A61K47/22 is incomplete pending reclassification of documents from groups A61K47/183 and A61K47/186. All groups listed in this Warning should be considered in order to perform a complete search.

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Type*	**Location**	**Old Warning notice**	**New/Modified Warning notice**
N	A61K47/26		Group A61K47/26 is incomplete pending reclassification of documents from groups A61K47/183 and A61K47/186. All groups listed in this Warning should be considered in order to perform a complete search.
N	A61K47/28		Group A61K47/28 is incomplete pending reclassification of documents from groups A61K47/183 and A61K47/186. All groups listed in this Warning should be considered in order to perform a complete search.

*N = new warning, M = modified warning, D = deleted warning

NOTE: The "Location" column only requires the symbol PRIOR to the location of the warning. No further directions such as "before" or "after" are required.

C. New, Modified or Deleted Note(s)

SUBCLASS A61K PREPARATION FOR MEDICAL, DENTAL OR TOILET PURPOSES

Type*	**Location**	**Old Note**	**New/Modified Note**
D	A61K41/0052	Delete all notes	
D	A61K47/34	Delete all notes	
D	A61K47/48007	Delete all notes	
D	A61K47/48015	Delete all notes	
D	A61K47/48038	Delete all notes	
D	A61K47/48046	Delete all notes	
D	A61K47/48069	Delete all notes	
D	A61K47/48076	Delete all notes	
D	A61K47/48084	Delete all notes	
D	A61K47/48092	Delete all notes	
D	A61K47/481	Delete all notes	
D	A61K47/48123	Delete all notes	
D	A61K47/4813	Delete all notes	
D	A61K47/48138	Delete all notes	
D	A61K47/48146	Delete all notes	
D	A61K47/48153	Delete all notes	
D	A61K47/48169	Delete all notes	
D	A61K47/4823	Delete all notes	
D	A61K47/48238	Delete all notes	
D	A61K47/48246	Delete all notes	
D	A61K47/48269	Delete all notes	
D	A61K47/48276	Delete all notes	
D	A61K47/4833	Delete all notes	
D	A61K47/48346	Delete all notes	
D	A61K47/48353	Delete all notes	
D	A61K47/48361	Delete all notes	
D	A61K47/48376	Delete all notes	
D	A61K47/48384	Delete all notes	
D	A61K47/48507	Delete all notes	
D	A61K47/48723	Delete all notes	
D	A61K47/48753	Delete all notes	
D	A61K47/48761	Delete all notes	
D	A61K47/48769	Delete all notes	
D	A61K47/48776	Delete all notes	
D	A61K47/488	Delete all notes	
D	A61K47/48815	Delete all notes	
D	A61K47/48823	Delete all notes	
D	A61K47/4883	Delete all notes	
D	A61K47/48861	Delete all notes	
D	A61K47/48869	Delete all notes	
D	A61K47/48876	Delete all notes	
D	A61K47/48884	Delete all notes	
D	A61K47/48892	Delete all notes	

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Type*	**Location**	**Old Note**	**New/Modified Note**
D	A61K49/1851	Delete all notes	

*N = new note, M = modified note, D = deleted note

NOTE: The “Location” column only requires the symbol PRIOR to the location of the note. No further directions such as “before” or “after” are required.

2. A. DEFINITIONS (new)

A61K 47/34

Relationship with other classification places

This group does not cover polyalkoxylated compounds, which are classified according to the derivatized compounds. The following list of references provides examples of such polyalkoxylated compounds together with their relevant group.

Limiting References

POE alkyl ethers	A61K 47/10

Informative references

PEG fatty acid esters	A61K 47/14
poloxamines	A61K 47/18
polysorbates	A61K 47/26
POE castor oil	A61K 47/44

A61K 47/50

Definition statement

This place covers:

Medicinal preparations containing conjugates. A conjugate is meant to define a pharmacologically/therapeutically-active agent or drug chemically bound (by covalent bonds or by complexation) to a modifying agent. The classification in this subgroup is based on this modifying agent. The "pharmacologically/therapeutically-active agent" covers a molecule used as the drug and linked to the modifying agent, or a molecule used as the drug and encapsulated/linked to a special physical/galenical form. The modifying agent is e.g. used to:
-modify the physico-chemical properties of the pharmacologically/therapeutically-active agent, e.g. to increase its solubility in bodily fluids,
-modify the pharmacokinetic properties, e.g. to increase the time of residence in the blood,
-modify the pharmacological activity (in case of e.g. codrugs or mutual drugs), or
-target specific sites in the body for delivery, i.e. receptors, cells, tissues or organs.

Informative References

Medicinal preparations containing organic active ingredients	A61K 31/00
Organic chemistry in general	C07
Labelling of peptides or proteins	C07K 1/13
Enzymes or proenzymes	C12N 9/00

Special rules of classification

In the subgroups of A61K 47/50, the classification is based on the non-active ingredient, i.e. the modifying agent.
However, for the conjugates of an antibody, the pharmacologically/therapeutically-active agent of the conjugate is also classified, in the subgroups of A61K 47/68. The modifying group must be part of a well-defined class of compounds.
The last place priority rule does not apply for A61K 47/50, i.e. all aspects of the invention are classified. E.g. a liposome modified on its external surface by a modifying agent, is classified both in A61K47/6911 and in the appropriate subgroup of A61K47/50, e.g. in A61K47/62 for a peptide/protein, and in the appropriate subgroup of A61K47/6835 for an antibody.
Targeted drug delivery systems as defined in A61K47/555, A61K47/66 and A61K47/6891 comprise more than one component. For example, in ADEPT, one component carries the enzyme to its target, and the other the prodrug. Although less detailed, the classification of conjugates in which the modifying component is a peptide

follows a classification similar to that in the field of new peptides or proteins, i.e. C07K 14/00 and subgroups. Similarly, the classification of conjugates in which the modifying component is an antibody, the classification of the characterising antibody follows a classification similar to that of new antibodies, C07K 16/00 and subgroups, again less detailed. For the specificity of the antibody, the same rules are followed as for the classification in C07K 16/00. For the specificity of the antibody, if the antibody is new, the corresponding class in C07K 16/00 and subgroups is also given.

The active agent is also classified in A61K 47/50 in two cases:

- if the modifying agent is also active: A61K 47/55, A61K 47/551, A61K47/552, and in the case of sugars A61K47/549;
- if the active agent is attached to an antibody as modifying agent: A61K47/68.

Glossary of terms

In this place, the following terms or expressions are used with the meaning indicated:

ADEPT	Antibody-Directed Enzyme-Prodrug Therapy
VDEPT	Virus-Directed Enzyme-Prodrug Therapy
PDEPT	Polymer-Directed Enzyme-Prodrug Therapy
ECTA	Enzyme-Catalyzed Therapeutic Agent

A61K 47/52

Informative References

Classic ion pairs of medicinal agents	A61K 31/00

A61K 47/543

Informative References

Fatty acid conjugates	A61K 47/542
Cholesterol conjugates	A61K 47/554

A61K 47/546

Informative References

Porphyrins used as photosensitizers in photodynamic therapy	A61K 41/0071, A61K 41/0076
Porphyrins used as fluorescent diagnostic optical agents administered in vivo	A61K 49/0036

Special rules of classification

Porphyrins used as photosensitizers in photodynamic therapy, where the photosensitizer is considered as the therapeutically active part, and modified by another compound, e.g. polymer or an antibody, should be classified in A61K 41/0071 or A61K 41/0076 in addition to the appropriate subgroup A61K 47/50 according to the modifying agent.

A61K 47/547

Informative References

Paramagnetic chelates used in MRI and not linked to by further compound, e.g. polymer, peptide, protein, antibody, small molecules like sugars	A61K49/101
Paramagnetic chelates used in MRI and conjugated to another compound, e.g. a polymer, a peptide, a protein, an antibody, a small molecule like a sugar	A61K49/06
Paramagnetic chelates used in MRI and conjugated to another compound not being used as therapeutic agent, according to the nature of the modifying agent	A61K49/085
Radiolabelled chelates	A61K51/0474
Radiolabelled chelates being linked to a further molecule, e.g. an organic compound, polymer, peptide, protein or polyamino acid, antibody	A61K51/0497, A61K51/065, A61K51/088, A61K51/1093

A61K 47/548

Informative References

Nucleic acid carriers	A61K47/549

A61K 47/549

Definition statement

This place covers:

Nucleic acids can be coding, non-coding, nucleic acid which being therapeutically-active or not, e.g. oligonucleotides, DNA, RNA, siRNA, and nucleic acid aptamers.

A61K 47/55

Informative References

Sugar, nucleoside, nucleotide, nucleic acid	A61K47/549

A61K 47/554

Definition statement

This place covers:

Cholesterol

Special rules of classification

Codrugs of pharmacologically active/therapeutically-active steroids are classified in this group and also in A61K47/55.

A61K 47/555

Definition statement

This place covers:

A targeting agent able to target specific cells or receptors in the body (T) being an organic compound, not being a peptide, protein or antibody.

Special rules of classification

The concept of "pre-targeting" covers the administration of the modifying agent, which is an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent, e.g. drug D, in several steps, their "binding" occurring at the in vivo targeted site.

It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug linked to a modifying agent M able to target the compound A.

The sequence involves the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to A and M may also be administered, e.g. during a clearing step.
Classification is made according to the nature of T in the subgroups of A61K47/555, A61K47/66, and A61K47/6891.
In A61K47/555 and its subgroups, if T is an organic compound, other than a peptide, protein or antibody, classification is also made according to the nature of organic compound T in the appropriate A61K47/54 subgroup. If T is a peptide, protein or antibody, classification is made in the corresponding A61K47/66 (peptide or protein) or A61K47/6891 (antibody) group.

A61K 47/556

Definition statement

This place covers:

Enzymes being used as group A, and being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D which being a substrate for A being administered. The enzyme A being able to cleave the conjugate M-D, which can be a prodrug. The drug D being thus released through enzymatic cleavage at particular targeted cells.

A61K 47/558

Definition statement

This place covers:

Chemical reactions inducing the cleavage of the pharmacologically or therapeutically active agent from the carrier while at the same time producing light.

Informative References

Conjugates being cleaved through activation by light in vivo in order to release the drug	A61K41/0042
Dyes or luminescent agents for optical diagnostic imaging	A61K49/001
Dyes or luminescent agents for photodynamic therapy	A61K41/0057

A61K 47/56

Informative References

Peptides, proteins, polyamino acids	A61K47/62
Antibodies	A61K47/68
Block copolymers	A61K47/56, A61K47/62

A61K 47/61

Informative References

Cyclodextrin being used to complex the drug	A61K47/6951
Proteoglycans as modifying agents attached to the pharmacologically or therapeutically active agents	A61K47/62

A61K 47/62

Informative References

Antibodies or immunoglobulins	A61K47/68
Peptidic linkers used to connect a drug and a modifying agent	A61K47/65

Special rules of classification

Special physical or galenic forms modified by covalent attachment or complexation of a protein, peptide or polyamino acid, are classified in A61K47/62 and additionally in A61K47/69, if considered relevant. E.g. a liposome modified on its surface by a peptide is classified in A61K47/6911 and in A61K47/62, a PLGA nanoparticle modified on its surface by a peptide is classified in A61K47/6937 and in A61K47/62.

A61K 47/64

Definition statement

This place covers:

Conjugates, wherein a peptide or protein being the pharmacologically or therapeutically active agent is linked to another peptide or protein being the modifying agent via chemical methods.
Chemically-produced peptides or protein-peptides or protein conjugates, the peptides or proteins used as modifying agents.

Informative References

The connection of the drug to the peptide, protein or polyamino acid can be by a direct covalent linkage or through a linker Fusion/chimeric proteins genetically produced	C07K2319/00

A61K 47/646

Informative References

Haptens, e.g. conjugates of morphine or nicotine and KLH inducing an immune response	A61K47/643

Special rules of classification

Haptens, e.g. conjugates of morphine or nicotine and KLH inducing an immune response, are classified both in this group and additionally in A61K47/643.

A61K 47/66

Definition statement

This place covers:

The concept of "pre-targeting" covers the administration of the modifying agent, i.e. an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent (drug D) in several steps, their "binding" occurring at the in vivo targeted site.

It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent T able to target specific cells or receptors in the body (T) linked to a compound A, and (ii) a conjugate D-M corresponding to the drug D linked to a modifying agent M, able to target the compound A.

T being a peptide or protein, not being an antibody.

The sequence involves the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to both A and M may also be administered, e.g. during a clearing step.

Informative References

M being biotin and A being a (strept)avidin or a derivative thereof	A61K47/665

Special rules of classification

Classification is made according to the nature of T in subgroups of A61K47/555, A61K47/66, and A61K47/6891.

A61K 47/67

Definition statement

This place covers:

Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT], VDEPT. An enzyme is used as group A in the sense of this group, being first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D, which is a substrate for A, is administered. The enzyme A is able to cleave the conjugate M-D, which can be a prodrug. The drug D is thus released through enzymatic cleavage at particular targeted cells.

A61K 47/6803

Definition statement

This place covers:

Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates. The modifying part is an antibody or immunoglobulin bearing at least one antigen-binding site.

Relationship with other classification places

Antibodies per se are classified in C07K16/00.

Informative References

Conjugates comprising a polymer or a polyamino acid	A61K47/6883, A61K47/6885

Special rules of classification

In this group, classification is made according to the nature of the drug, i.e. the pharmacologically or therapeutically active agents in the antibody conjugate. If the nature of the antibody in a specific conjugate is known, it is additionally classified in A61K47/6835. If the conjugate comprises also a polymer or a polyamino acid, then classification is also made in A61K47/6883 or A61K47/6885.

A61K 47/6835

Definition statement

This place covers:

Modifying agents being a well-defined antibody or immunoglobulin bearing at least one antigen-binding site

Informative References

Porphyrins used as photosensitizers in photodynamic therapy, the photosensitizer being considered as the therapeutically active part, and modified by an antibody	A61K41/0071

Special rules of classification

According to the nature of the antibody, classification is additionally made in the appropriate groups of A61K47/6835. The pharmacologically or therapeutically active agent in the antibody conjugate is additionally classified in A61K47/6803, whenever considered appropriate.

A61K 47/6891

Definition statement

This place covers:

Pre-targeting systems involving an antibody for targeting specific cells. The concept of "pre-targeting" covers the administration of the modifying agent, i.e. an agent able to target specific cells in the body, and of the pharmacologically or therapeutically active agent (drug D) in several steps, their "binding" occurring at the in vivo targeted site.

It involves administration in at least two steps, for example, (i) a conjugate T-A corresponding to a targeting agent able to target specific cells or receptors in the body (T) linked to a compound A (wherein T is an antibody), and (ii) a conjugate D-M corresponding to the drug linked to a modifying agent M, able to target the compound A.

The sequence involves e.g. the administration of T-A and then D-M. Between step (i) and step (ii), a further compound able to bind to A and M may also be administered, e.g. during a clearing step.

Special rules of classification

Classification is additionally made according to the nature of T in A61K47/555, A61K47/66, and A61K47/6893. Classification is also made according to the nature of the antibody in A61K47/6835. If M and A form a pair of biotin and (strept)avidin, or derivatives of biotin and (strept)avidin, then classification is also made in A61K47/6898.

A61K 47/6898

Definition statement

This place covers:

Avidin-biotin systems, wherein at least one avidin- or biotin-conjugated antibody is used in a two- or three-steps pretargeting system, e.g. wherein M and A in form a pair of biotin and (strept)avidin, or derivatives of biotin and (strept)avidin.

A61K 47/6899

Definition statement

This place covers:

Antibody Directed Enzyme Prodrug Therapy [ADEPT]. An enzyme is used as group A and is first targeted to specific cells via administration of the conjugate T-A. Then, the conjugate M-D, which is a substrate for A, is administered. The enzyme A is able to cleave the conjugate M-D, which can be a prodrug. The drug D is thus released through enzymatic cleavage at particular targeted cells.

A61K 47/69

Definition statement

This place covers:

Conjugates characterized by a special physical or galenical form.

The conjugates correspond either (i) to a pharmacologically or therapeutically active agent complexed/covalently linked to the special physical or galenical form, e.g. on the surface of a polymeric nanoparticle or liposome, or to polymeric chains in the matrix of a polymeric gel, or (ii) to a special physical or galenical form encapsulating the pharmacologically or therapeutically active agent and modified on its surface or matrix by a modifying agent.

Special rules of classification

In case of (i) above, classification is made according to the nature of the special physical or galenical form in this group. Additionally the compound, to which the pharmacologically or therapeutically active agent is linked, is classified in the relevant subgroups of A61K 47/50, e.g. A61K47/544 in case of a drug linked to a phospholipid and inserted in the bilayer surface of a liposome.
In case of (ii) above, classification is made according to the nature of the modifying agent. Physical or galenical forms not modified by a modifying agent and/or wherein the pharmacologically or therapeutically active agent is not complexed/covalently linked to said forms, are not classified in A61K47/50, but in A61K9/00.

A61K 47/6901

Informative References

Encapsulation in cells	A61K9/5068
Encapsulation in a virus capsid	A61K9/5184

A61K 47/6907

Informative References

Simple encapsulation of a drug in micelle	A61K9/1075

Special rules of classification

Micelles modified by a polymer because they incorporate a polymer-lipid conjugate are only classified in this group, if the polymer modifying the lipid is unusual. Micelles, which are pegylated because they incorporate a pegylated lipid, are not classified in this group, but in A61K9/1075.

Glossary of terms

In this place, the following terms or expressions are used with the meaning indicated:

Microemulsion	means that the dispersed phase being in the form of globules having a diameter above or equal to 1 micrometer.
Nanoemulsion	means that the dispersed phase being in the form of globules having a diameter below 1 micrometer.
Micelles	comprise a monolayer of surfactant molecules that are aggregated head-to-head and tail-to-tail, thus forming a small spherical particle; micelles can be normal, i.e. the surfactant heads are hydrophilic, or inverse.

A61K 47/6911

Definition statement

This place covers:

Liposomes, i.e. bi-layered vesicles, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent.

Informative References

Encapsulation of a drug, which is not functionalised on its surface by a modifying agent	A61K9/127
Antibodies	A61K47/6913

Special rules of classification

Liposomes, which are modified by a polymer because they incorporate a polymer-lipid conjugate are only classified in this group, if the polymer modifying the lipid is unusual.
Liposomes, which are PEGylated because they incorporate a PEGylated lipid, are not classified in this group, but in A61K9/1271.
When the surface of the liposome is functionalised by a modifying agent, classification is also made according to the nature of this modifying agent, e.g. a liposome modified on its surface by a peptide is classified in this group and additionally in A61K47/605.
Liposomes, wherein the pharmacologically or therapeutically active agent is linked to a phospholipid of the liposomal surface, are classified in this group and additionally in A61K47/544.

A61K 47/6913

Special rules of classification

Classification is also made according to the nature of the antibody in the appropriate subgroup of A61K47/6835.

A61K 47/6915

Definition statement

This place covers:

Polymersomes, i.e. a liposome with polymerisable or polymerized bilayer-forming substances.

Special rules of classification

Liposomes comprising polymers grafted on their surface are not classified in this group, but in A61K47/6911, if the polymer is unusual, or in A61K9/1271.

A61K 47/6923

Definition statement

This place covers:

Inorganic particles, e.g. ceramic particles, silica particles, ferrite, synsorb

Special rules of classification

When the inorganic particle is a magnetic particle, being guided from outside the body with the means of a magnetic field, classification is additionally made in A61K41/00.

A61K 47/6925

Definition statement

This place covers:

Microcapsules, nanocapsules, microbubbles or nanobubbles, i.e. a hollow or gas-filled microparticle or nanoparticle or sphere, a gas-filled microparticle or nanoparticle for use in therapy.

Informative References

Micro- or nano-bubbles used for ultrasound imaging	A61K49/223, A61K49/225

Special rules of classification

Pharmacologically or therapeutically active agents released from a microcapsule or nanocapsule by acoustic/ultrasound activation are also classified in A61K41/0028 and A61K9/0009.

A61K 47/6927

Definition statement

This place covers:

Solid microparticles having no hollow or gas-filled core, wherein its size or diameter is higher or equal to 1 micrometer.

A61K 47/6929

Definition statement

This place covers:

Nanoparticles, e.g. immuno-nanoparticles, wherein its size or diameter is smaller than 1 micrometer.

Special rules of classification

Classification is also made according to the nature of the antibody with the appropriate subgroup of A61K47/6835.

2. B. DEFINITIONS QUICK FIX

Symbol	**Location of change** (e.g., section title)	**Existing reference symbol or text**	**Action; New symbol; New text**
A61K 8/97	Limiting references	Condensed tannins, e.g. proantho cyanidines A61K8/498 Hydrolysable tannins, e.g. glycosides A61K8/602	Delete the entire **Limiting references** section.
A61K 8/97			Insert the following new **Informative references** section: ***Informative references*** Condensed tannins, e.g. proanthocyanidines A61K8/498 Hydrolysable tannins, e.g. glycosides A61K8/602
A61K 8/99	Special Rules of classification	A61K 2201/70 or A61K 2201/702	Replace both symbols with: A61K2800/85
A61K 47/00	Definition statement	A61K47/48	Replace with: A61K47/50
A61K 47/00	Relationship with other classification places	A61K47/48	Replace with: A61K47/50
A61K 47/00	Limiting references	Nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18 Preparations containing radioactive substances A61K51/12	Delete the entire **Limiting** references section.
A61K 47/00			Insert the following new **Informative** references section. ***Informative references*** Nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18 Preparations containing radioactive substances A61K51/12
A61K 47/48			Delete entire definitions
A61K 47/48092			Delete entire definitions
A61K 47/481			Delete entire definitions

NOTES:

- The table above is used for corrections or modifications to existing definitions, e.g. delete an entire definition or part thereof; propose new wording or modify wording of a section, change the symbol the definition is associated with, change or delete a reference symbol, etc.
- Do not delete (F) symbol definitions.

3. REVISION CONCORDANCE LIST (RCL)

Type*	**From CPC Symbol (existing)**	**To CPC Symbol(s)**
C	A61K 8/97	A61K 8/97, A61K 8/9706, A61K 8/9711, A61K 8/9717, A61K 8/9722, A61K 8/9728, A61K 8/9733, A61K 8/9739, A61K 8/9741, A61K 8/9749, A61K 8/9755, A61K 8/9761, A61K 8/9767, A61K 8/9771, A61K 8/9778, A61K 8/9783, A61K 8/9789, A61K 8/9794
Q	A61K 8/9706	A61K 8/9706, A61K 8/9711, A61K 8/9717, A61K 8/9722, A61K 8/9728, A61K 8/9733, A61K 8/9739, A61K 8/9741, A61K 8/9749, A61K 8/9755, A61K 8/9761, A61K 8/9767, A61K 8/9771, A61K 8/9778, A61K 8/9783, A61K 8/9789, A61K 8/9794
D	A61K 8/975	<administrative transfer to A61K 8/9706>
C	A61K 8/99	A61K 8/99, A61K 8/9706, A61K 8/9728
C	A61K 47/183	A61K 47/183, A61K 47/20, A61K 47/22, A61K 47/26, A61K 47/28
C	A61K 47/186	A61K 47/186, A61K 47/20, A61K 47/22, A61K 47/26, A61K 47/28
D	A61K 47/48	<administrative transfer to A61K 47/50>
D	A61K 47/48007	<administrative transfer to A61K 47/51>
D	A61K 47/48015	<administrative transfer to A61K 47/52>
D	A61K 47/48023	<administrative transfer to A61K 47/54>
D	A61K 47/4803	<administrative transfer to A61K 47/541>
D	A61K 47/48038	<administrative transfer to A61K 47/542>
D	A61K 47/48046	<administrative transfer to A61K 47/543>
D	A61K 47/48053	<administrative transfer to A61K 47/544>
D	A61K 47/48061	<administrative transfer to A61K 47/545>
D	A61K 47/48069	<administrative transfer to A61K 47/546>
D	A61K 47/48076	<administrative transfer to A61K 47/547>
D	A61K 47/48084	<administrative transfer to A61K 47/548>
D	A61K 47/48092	<administrative transfer to A61K 47/549>
D	A61K 47/481	<administrative transfer to A61K 47/55>
D	A61K 47/48107	<administrative transfer to A61K 47/551>
D	A61K 47/48115	<administrative transfer to A61K 47/552>
D	A61K 47/48123	<administrative transfer to A61K 47/554>
D	A61K 47/4813	<administrative transfer to A61K 47/555>
D	A61K 47/48138	<administrative transfer to A61K 47/556>
D	A61K 47/48146	<administrative transfer to A61K 47/557>
D	A61K 47/48153	<administrative transfer to A61K 47/558>
D	A61K 47/48161	<administrative transfer to A61K 47/559>
D	A61K 47/48169	<administrative transfer to A61K 47/56>
D	A61K 47/48176	<administrative transfer to A61K 47/58>
D	A61K 47/48184	<administrative transfer to A61K 47/585>
D	A61K 47/48192	<administrative transfer to A61K 47/59>
D	A61K 47/482	<administrative transfer to A61K 47/593>
D	A61K 47/48207	<administrative transfer to A61K 47/595>

Type*	**From CPC Symbol (existing)**	**To CPC Symbol(s)**
D	A61K 47/48215	<administrative transfer to A61K 47/60>
D	A61K 47/48223	<administrative transfer to A61K 47/605>
D	A61K 47/4823	<administrative transfer to A61K 47/61>
D	A61K 47/48238	<administrative transfer to A61K 47/62>
D	A61K 47/48246	<administrative transfer to A61K 47/64>
D	A61K 47/48253	<administrative transfer to A61K 47/641>
D	A61K 47/48261	<administrative transfer to A61K 47/6415>
D	A61K 47/48269	<administrative transfer to A61K 47/642>
D	A61K 47/48276	<administrative transfer to A61K 47/6425>
D	A61K 47/48284	<administrative transfer to A61K 47/643>
D	A61K 47/48292	<administrative transfer to A61K 47/6435>
D	A61K 47/483	<administrative transfer to A61K 47/644>
D	A61K 47/48307	<administrative transfer to A61K 47/6445>
D	A61K 47/48315	<administrative transfer to A61K 47/645>
D	A61K 47/48323	<administrative transfer to A61K 47/6455>
D	A61K 47/4833	<administrative transfer to A61K 47/646>
D	A61K 47/48338	<administrative transfer to A61K 47/65>
D	A61K 47/48346	<administrative transfer to A61K 47/66>
D	A61K 47/48353	<administrative transfer to A61K 47/665>
D	A61K 47/48361	<administrative transfer to A61K 47/67>
D	A61K 47/48369	<administrative transfer to A61K 47/68>
D	A61K 47/48376	<administrative transfer to A61K 47/6801>
D	A61K 47/48384	<administrative transfer to A61K 47/6803>
D	A61K 47/48392	<administrative transfer to A61K 47/6805>
D	A61K 47/484	<administrative transfer to A61K 47/6807>
D	A61K 47/48407	<administrative transfer to A61K 47/6809>
D	A61K 47/48415	<administrative transfer to A61K 47/6811>
D	A61K 47/48423	<administrative transfer to A61K 47/6813>
D	A61K 47/4843	<administrative transfer to A61K 47/6815>
D	A61K 47/48438	<administrative transfer to A61K 47/6817>
D	A61K 47/48446	<administrative transfer to A61K 47/6819>
D	A61K 47/48453	<administrative transfer to A61K 47/6821>
D	A61K 47/48461	<administrative transfer to A61K 47/6823>
D	A61K 47/48469	<administrative transfer to A61K 47/6825>
D	A61K 47/48476	<administrative transfer to A61K 47/6827>
D	A61K 47/48484	<administrative transfer to A61K 47/6829>
D	A61K 47/48492	<administrative transfer to A61K 47/6831>
D	A61K 47/485	<administrative transfer to A61K 47/6833>
D	A61K 47/48507	<administrative transfer to A61K 47/6835>
D	A61K 47/48515	<administrative transfer to A61K 47/6835>
D	A61K 47/48523	<administrative transfer to A61K 47/6839>
D	A61K 47/4853	<administrative transfer to A61K 47/6841>
D	A61K 47/48538	<administrative transfer to A61K 47/6843>
D	A61K 47/48546	<administrative transfer to A61K 47/6845>
D	A61K 47/48553	<administrative transfer to A61K 47/6847>
D	A61K 47/48561	<administrative transfer to A61K 47/6849>
D	A61K 47/48569	<administrative transfer to A61K 47/6851>
D	A61K 47/48576	<administrative transfer to A61K 47/6853>
D	A61K 47/48584	<administrative transfer to A61K 47/6855>

Type*	**From CPC Symbol (existing)**	**To CPC Symbol(s)**
D	A61K 47/48592	<administrative transfer to A61K 47/6857>
D	A61K 47/486	<administrative transfer to A61K 47/6859>
D	A61K 47/48607	<administrative transfer to A61K 47/6861>
D	A61K 47/48615	<administrative transfer to A61K 47/6863>
D	A61K 47/48623	<administrative transfer to A61K 47/6865>
D	A61K 47/4863	<administrative transfer to A61K 47/6867>
D	A61K 47/48638	<administrative transfer to A61K 47/6869>
D	A61K 47/48646	<administrative transfer to A61K 47/6871>
D	A61K 47/48653	<administrative transfer to A61K 47/6873>
D	A61K 47/48661	<administrative transfer to A61K 47/6875>
D	A61K 47/48669	<administrative transfer to A61K 47/6877>
D	A61K 47/48676	<administrative transfer to A61K 47/6879>
D	A61K 47/48684	<administrative transfer to A61K 47/6881>
D	A61K 47/48692	<administrative transfer to A61K 47/6883>
D	A61K 47/487	<administrative transfer to A61K 47/6885>
D	A61K 47/48707	<administrative transfer to A61K 47/6887>
D	A61K 47/48715	<administrative transfer to A61K 47/6889>
D	A61K 47/48723	<administrative transfer to A61K 47/6891>
D	A61K 47/4873	<administrative transfer to A61K 47/6893>
D	A61K 47/48738	<administrative transfer to A61K 47/6895>
D	A61K 47/48746	<administrative transfer to A61K 47/6897>
D	A61K 47/48753	<administrative transfer to A61K 47/6898>
D	A61K 47/48761	<administrative transfer to A61K 47/6899>
D	A61K 47/48769	<administrative transfer to A61K 47/69>
D	A61K 47/48776	<administrative transfer to A61K 47/6901>
D	A61K 47/48784	<administrative transfer to A61K 47/6903>
D	A61K 47/48792	<administrative transfer to A61K 47/6905>
D	A61K 47/488	<administrative transfer to A61K 47/6907>
D	A61K 47/48807	<administrative transfer to A61K 47/6909>
D	A61K 47/48815	<administrative transfer to A61K 47/6911>
D	A61K 47/48823	<administrative transfer to A61K 47/6913>
D	A61K 47/4883	<administrative transfer to A61K 47/6915>
D	A61K 47/48838	<administrative transfer to A61K 47/6917>
D	A61K 47/48846	<administrative transfer to A61K 47/6919>
D	A61K 47/48853	<administrative transfer to A61K 47/6921>
D	A61K 47/48861	<administrative transfer to A61K 47/6923>
D	A61K 47/48869	<administrative transfer to A61K 47/6925>
D	A61K 47/48876	<administrative transfer to A61K 47/6927>
D	A61K 47/48884	<administrative transfer to A61K 47/6929>
D	A61K 47/48892	<administrative transfer to A61K 47/6931>
D	A61K 47/489	<administrative transfer to A61K 47/6933>
D	A61K 47/48907	<administrative transfer to A61K 47/6935>
D	A61K 47/48915	<administrative transfer to A61K 47/6937>
D	A61K 47/48923	<administrative transfer to A61K 47/6939>
D	A61K 47/4893	<administrative transfer to A61K 47/6941>
D	A61K 47/48938	<administrative transfer to A61K 47/6943>
D	A61K 47/48946	<administrative transfer to A61K 47/6925>
D	A61K 47/48953	<administrative transfer to A61K 47/6925>
D	A61K 47/48961	<administrative transfer to A61K 47/6949>

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Type*	**From CPC Symbol (existing)**	**To CPC Symbol(s)**
D	A61K 47/48969	<administrative transfer to A61K 47/6951>
D	A61K 47/48976	<administrative transfer to A61K 47/6953>
D	A61K 47/48984	<administrative transfer to A61K 47/6955>
D	A61K 47/48992	<administrative transfer to A61K 47/6957>

* C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; D = deleted entries.

NOTES:

- Only C, D, F and Q type entries are included in the table above.
- When multiple symbols are included in the "To" column, avoid using ranges of symbols in order to be as precise as possible.
- For administrative transfer of documents, the following text should be used: "< administrative transfer to XX>" or "<administrative transfer to XX and YY simultaneously>" when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be "invention information", unless otherwise indicated, and to 2000 series groups is assumed to be "additional information".

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

CPC	**IPC**	**Action***
A61K 8/9706	A61K 8/9706	New
A61K 8/9711	A61K 8/9711	New
A61K 8/9717	A61K 8/9717	New
A61K 8/9722	A61K 8/9722	New
A61K 8/9728	A61K 8/9728	New
A61K 8/9733	A61K 8/9733	New
A61K 8/9739	A61K 8/9739	New
A61K 8/9741	A61K 8/9741	New
A61K 8/9749	A61K 8/9749	New
A61K8/975		Delete
A61K 8/9755	A61K 8/9755	New
A61K 8/9761	A61K 8/9761	New
A61K 8/9767	A61K 8/9767	New
A61K 8/9771	A61K 8/9771	New
A61K 8/9778	A61K 8/9778	New
A61K 8/9783	A61K 8/9783	New
A61K 8/9789	A61K 8/9789	New
A61K 8/9794	A61K 8/9794	New
A61K 47/48		Delete
A61K 47/48007		Delete
A61K 47/48015		Delete
A61K 47/48023		Delete
A61K 47/4803		Delete
A61K 47/48038		Delete
A61K 47/48046		Delete
A61K 47/48053		Delete
A61K 47/48061		Delete
A61K 47/48069		Delete
A61K 47/48076		Delete
A61K 47/48084		Delete
A61K 47/48092		Delete
A61K 47/481		Delete
A61K 47/48107		Delete
A61K 47/48115		Delete
A61K 47/48123		Delete
A61K 47/4813		Delete
A61K 47/48138		Delete
A61K 47/48146		Delete
A61K 47/48153		Delete
A61K 47/48161		Delete
A61K 47/48169		Delete

CPC	**IPC**	**Action***
A61K 47/48176		Delete
A61K 47/48184		Delete
A61K 47/48192		Delete
A61K 47/482		Delete
A61K 47/48207		Delete
A61K 47/48215		Delete
A61K 47/48223		Delete
A61K 47/4823		Delete
A61K 47/48238		Delete
A61K 47/48246		Delete
A61K 47/48253		Delete
A61K 47/48261		Delete
A61K 47/48269		Delete
A61K 47/48276		Delete
A61K 47/48284		Delete
A61K 47/48292		Delete
A61K 47/483		Delete
A61K 47/48307		Delete
A61K 47/48315		Delete
A61K 47/48323		Delete
A61K 47/4833		Delete
A61K 47/48338		Delete
A61K 47/48346		Delete
A61K 47/48353		Delete
A61K 47/48361		Delete
A61K 47/48369		Delete
A61K 47/48376		Delete
A61K 47/48384		Delete
A61K 47/48392		Delete
A61K 47/484		Delete
A61K 47/48407		Delete
A61K 47/48415		Delete
A61K 47/48423		Delete
A61K 47/4843		Delete
A61K 47/48438		Delete
A61K 47/48446		Delete
A61K 47/48453		Delete
A61K 47/48461		Delete
A61K 47/48469		Delete
A61K 47/48476		Delete
A61K 47/48484		Delete
A61K 47/48492		Delete
A61K 47/485		Delete
A61K 47/48507		Delete
A61K 47/48515		Delete
A61K 47/48523		Delete

CPC	**IPC**	**Action***
A61K 47/4853		Delete
A61K 47/48538		Delete
A61K 47/48546		Delete
A61K 47/48553		Delete
A61K 47/48561		Delete
A61K 47/48569		Delete
A61K 47/48576		Delete
A61K 47/48584		Delete
A61K 47/48592		Delete
A61K 47/486		Delete
A61K 47/48607		Delete
A61K 47/48615		Delete
A61K 47/48623		Delete
A61K 47/4863		Delete
A61K 47/48638		Delete
A61K 47/48646		Delete
A61K 47/48653		Delete
A61K 47/48661		Delete
A61K 47/48669		Delete
A61K 47/48676		Delete
A61K 47/48684		Delete
A61K 47/48692		Delete
A61K 47/487		Delete
A61K 47/48707		Delete
A61K 47/48715		Delete
A61K 47/48723		Delete
A61K 47/4873		Delete
A61K 47/48738		Delete
A61K 47/48746		Delete
A61K 47/48753		Delete
A61K 47/48761		Delete
A61K 47/48769		Delete
A61K 47/48776		Delete
A61K 47/48784		Delete
A61K 47/48792		Delete
A61K 47/488		Delete
A61K 47/48807		Delete
A61K 47/48815		Delete
A61K 47/48823		Delete
A61K 47/4883		Delete
A61K 47/48838		Delete
A61K 47/48846		Delete
A61K 47/48853		Delete
A61K 47/48861		Delete
A61K 47/48869		Delete
A61K 47/48876		Delete

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

CPC	**IPC**	**Action***
A61K 47/48884		Delete
A61K 47/48892		Delete
A61K 47/489		Delete
A61K 47/48907		Delete
A61K 47/48915		Delete
A61K 47/48923		Delete
A61K 47/4893		Delete
A61K 47/48938		Delete
A61K 47/48946		Delete
A61K 47/48953		Delete
A61K 47/48961		Delete
A61K 47/48969		Delete
A61K 47/48976		Delete
A61K 47/48984		Delete
A61K 47/48992		Delete
A61K 47/50	A61K 47/50	New
A61K 47/51	A61K 47/51	New
A61K 47/52	A61K 47/52	New
A61K 47/54	A61K 47/54	New
A61K 47/541	A61K 47/54	New
A61K 47/542	A61K 47/54	New
A61K 47/543	A61K 47/54	New
A61K 47/544	A61K 47/54	New
A61K 47/545	A61K 47/54	New
A61K 47/546	A61K 47/54	New
A61K 47/547	A61K 47/54	New
A61K 47/548	A61K 47/54	New
A61K 47/549	A61K 47/54	New
A61K 47/55	A61K 47/55	New
A61K 47/551	A61K 47/55	New
A61K 47/552	A61K 47/55	New
A61K 47/554	A61K 47/54	New
A61K 47/555	A61K 47/54	New
A61K 47/556	A61K 47/54	New
A61K 47/557	A61K 47/54	New
A61K 47/558	A61K 47/54	New
A61K 47/559	A61K 47/54	New
A61K 47/56	A61K 47/56	New
A61K 47/58	A61K 47/58	New
A61K 47/585	A61K 47/58	New
A61K 47/59	A61K 47/59	New
A61K 47/593	A61K 47/59	New
A61K 47/595	A61K 47/59	New
A61K 47/60	A61K 47/60	New
A61K 47/605	A61K 47/58	New
A61K 47/61	A61K 47/61	New

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

CPC	**IPC**	**Action***
A61K 47/62	A61K 47/62	New
A61K 47/64	A61K 47/64	New
A61K 47/641	A61K 47/64	New
A61K 47/6415	A61K 47/64	New
A61K 47/642	A61K 47/64	New
A61K 47/6425	A61K 47/64	New
A61K 47/643	A61K 47/64	New
A61K 47/6435	A61K 47/64	New
A61K 47/644	A61K 47/64	New
A61K 47/6445	A61K 47/64	New
A61K 47/645	A61K 47/64	New
A61K 47/6455	A61K 47/64	New
A61K 47/646	A61K 47/64	New
A61K 47/65	A61K 47/65	New
A61K 47/66	A61K 47/66	New
A61K 47/665	A61K 47/66	New
A61K 47/67	A61K 47/66	New
A61K 47/68	A61K 47/68	New
A61K 47/6801	A61K 47/68	New
A61K 47/6803	A61K 47/68	New
A61K 47/6805	A61K 47/68	New
A61K 47/6807	A61K 47/68	New
A61K 47/6809	A61K 47/68	New
A61K 47/6811	A61K 47/68	New
A61K 47/6813	A61K 47/68	New
A61K 47/6815	A61K 47/68	New
A61K 47/6817	A61K 47/68	New
A61K 47/6819	A61K 47/68	New
A61K 47/6821	A61K 47/68	New
A61K 47/6823	A61K 47/68	New
A61K 47/6825	A61K 47/68	New
A61K 47/6827	A61K 47/68	New
A61K 47/6829	A61K 47/68	New
A61K 47/6831	A61K 47/68	New
A61K 47/6833	A61K 47/68	New
A61K 47/6835	A61K 47/68	New
A61K 47/6839	A61K 47/68	New
A61K 47/6841	A61K 47/68	New
A61K 47/6843	A61K 47/68	New
A61K 47/6845	A61K 47/68	New
A61K 47/6847	A61K 47/68	New
A61K 47/6849	A61K 47/68	New
A61K 47/6851	A61K 47/68	New
A61K 47/6853	A61K 47/68	New
A61K 47/6855	A61K 47/68	New
A61K 47/6857	A61K 47/68	New

CPC	**IPC**	**Action***
A61K 47/6859	A61K 47/68	New
A61K 47/6861	A61K 47/68	New
A61K 47/6863	A61K 47/68	New
A61K 47/6865	A61K 47/68	New
A61K 47/6867	A61K 47/68	New
A61K 47/6869	A61K 47/68	New
A61K 47/6871	A61K 47/68	New
A61K 47/6873	A61K 47/68	New
A61K 47/6875	A61K 47/68	New
A61K 47/6877	A61K 47/68	New
A61K 47/6879	A61K 47/68	New
A61K 47/6881	A61K 47/68	New
A61K 47/6883	A61K 47/68	New
A61K 47/6885	A61K 47/68	New
A61K 47/6887	A61K 47/68	New
A61K 47/6889	A61K 47/68	New
A61K 47/6891	A61K 47/68	New
A61K 47/6893	A61K 47/68	New
A61K 47/6895	A61K 47/68	New
A61K 47/6897	A61K 47/68	New
A61K 47/6898	A61K 47/68	New
A61K 47/6899	A61K 47/68	New
A61K 47/69	A61K 47/69	New
A61K 47/6901	A61K 47/69	New
A61K 47/6903	A61K 47/69	New
A61K 47/6905	A61K 47/69	New
A61K 47/6907	A61K 47/69	New
A61K 47/6909	A61K 47/69	New
A61K 47/6911	A61K 47/69	New
A61K 47/6913	A61K 47/69	New
A61K 47/6915	A61K 47/69	New
A61K 47/6917	A61K 47/69	New
A61K 47/6919	A61K 47/69	New
A61K 47/6921	A61K 47/69	New
A61K 47/6923	A61K 47/69	New
A61K 47/6925	A61K 47/69	New
A61K 47/6927	A61K 47/69	New
A61K 47/6929	A61K 47/69	New
A61K 47/6931	A61K 47/69	New
A61K 47/6933	A61K 47/69	New
A61K 47/6935	A61K 47/69	New
A61K 47/6937	A61K 47/69	New
A61K 47/6939	A61K 47/69	New
A61K 47/6941	A61K 47/69	New
A61K 47/6943	A61K 47/69	New
A61K 47/6949	A61K 47/69	New

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

CPC	**IPC**	**Action***
A61K 47/6951	A61K 47/69	New
A61K 47/6953	A61K 47/69	New
A61K 47/6955	A61K 47/69	New
A61K 47/6957	A61K 47/69	New

*Action column:

- For an (N) or (Q) entry, provide an IPC symbol and complete the Action column with “NEW.”
- For an existing CPC main trunk entry or indexing entry where the existing IPC symbol needs to be changed, provide an updated IPC symbol and complete the Action column with “UPDATED.”
- For a (D) CPC entry or indexing entry complete the Action column with “DELETE.” IPC symbol does not need to be included in the IPC column.
- For an (N) 2000 series CPC entry which is positioned within the main trunk scheme (breakdown code) provide an IPC symbol and complete the action column with “NEW”.
- For an (N) 2000 series CPC entry positioned at the end of the CPC scheme (orthogonal code), with no IPC equivalent, complete the IPC column with “CPCONLY” and complete the action column with “NEW”.

NOTES:

- F symbols are not included in the CICL table above.
- E and M symbols are not included in the CICL table above unless a change to the existing IPC is desired.

5. CROSS-REFERENCE LIST (CRL)

Scheme references impacted by this revision project

Location of reference to be changed	**Referenced subclass or group to be changed**	**Action; New reference symbol; New text**
A61K9/141	A61K47/48	A61K47/50
A61K9/1676	A61K47/48853	A61K47/6921
A61K9/51	A61K47/48	A61K47/50
A61K39/395	A61K47/48	A61K47/50
A61K49/0036	A61K47/48069	A61K47/546
A61K51/0404	A61K47/48169	A61K47/56

Definitions references impacted by this revision project

Location of reference to be changed	**Referenced subclass or group to be changed**	**Section of definition**	**Action; New reference symbol; New text**
A61K 9/00	A61K 47/48	Relationships with other classification places	A61K 47/50
A61K 31/00	A61K 47/48	Informative references	A61K 47/50
A61K 33/00	A61K 47/48	Informative references	A61K 47/50
A61K 38/00	A61K 47/48 (Referenced with A61K47/42)	Limiting references	A61K 47/50
A61K 38/00	A61K 47/48238	Limiting references	A61K 47/62
A61K 41/00	A61K 47/4893	Definition statement	A61K 47/6941
A61K 41/00	A61K 47/48	Relationships with other classification places	A61K 47/50
A61K 41/00	A61K 47/48	Special rules of classification	A61K 47/50
A61K45/06	A61K47/48	Informative references	A61K47/50
A61K 49/001	A61K 47/48069	Definition statement	A61K 47/546

CPC NOTICE OF CHANGES 365

DATE: AUGUST 1, 2017

PROJECT RP0407

Location of reference to be changed	**Referenced subclass or group to be changed**	**Section of definition**	**Action; New reference symbol; New text**
A61K 49/06	A61K 47/48169	Definition statement	A61K 47/56
A61K 49/06	A61K 47/48238	Definition statement	A61K 47/62
A61K 49/06	A61K 47/48861	Limiting references	A61K 47/6923
B01J 13/00	A61K 47/48946	Informative references	Delete entire row
B01J 13/00	A61K 47/48953	Informative references	Microcapsules or nanocapsules comprising a medicinal preparation chemically bound to a non-active ingredient, e.g. polymer-drug conjugate A61K 47/6925
C07K 1/13	A61K 47/48238	Informative references	A61K 47/62
C07K 1/13	A61K 47/48	Informative references	A61K 47/50
C07K 5/00	A61K 47/48238	Informative references	A61K 47/62
C07K 5/00	A61K 47/48376	Informative references	A61K 47/6801
C07K 5/00	A61K 47/48	Informative references	A61K 47/50
C07K 16/00	A61K 47/48369	Informative references	A61K 47/68
C07K 16/00	A61K 47/48369	Application-oriented references	A61K 47/68
C07K 16/00	A61K 47/48369	Special rules of classification	A61K 47/68
C08B	A61K 47/48	Application-oriented references	A61K 47/50
C08B 37/00	A61K 47/48969	Relationships with other classification places	A61K 47/6951
C08G 83/002	A61K 47/487	Informative references	A61K 47/6885
C08G 83/003	A61K 47/487	Informative references	A61K 47/6885
C08H 1/00	A61K 47/48238	Relationships with other	A61K 47/62

Location of reference to be changed	**Referenced subclass or group to be changed**	**Section of definition**	**Action; New reference symbol; New text**
		classification places	
C08J 3/00	A61K 47/48	Application-oriented references	A61K 47/50
C08J 5/00	A61K 47/48	Application-oriented references	A61K 47/50
C12P	A61K 8/975	Limiting references	A61K 8/9706

NOTES:

- The CRL tables above are used for changes to locations **outside** of the project scope. Changes to references in scheme titles or definitions inside the project scope will be reflected in the "scheme change" template or one of the "definition" templates.
- In addition to other changes proposed in the tables above, in the column titled "Referenced subclass or group to be changed," **referenced** D symbols should indicate an action of "delete" or should indicate a replacement symbol and **referenced** F symbols should indicate a replacement symbol.
- When a reference is deleted, text related to that reference will also be deleted unless other references or a range of references associated with the same text remain.